Wire Stories
BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025
CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–$BGNE #BTKi–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines...